Labeled QAB149- supporting new drug development

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 53, Issue 5-6, 2010, Pages 454-456

  Markus, Bohdan ^a   Wu, Amy ^a   Ray, Tapan ^a   Ciszewska, Grazyna ^a   Jones, Lawrence ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

ADME and HADME studies; Asthma and COPD; Indacaterol (QAB149); Stable label M+4 and carbon 14 label QAB149; Tritium (3H)

Indexed keywords

CARBON; PULMONARY DISEASES;

ADME AND HADME STUDY; ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE; CARBON 14; CARBON-13; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; DRUG DEVELOPMENT; INDACATEROL (QAB149); STABLE LABEL [M+4] AND CARBON-14 LABEL QAB149; SYNTHESISED; TRITIUM (3H);

TRITIUM;

CARBON 13; CARBON 14; DEUTERIUM; INDACATEROL; TRITIUM;

CONFERENCE PAPER; DRUG PURIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; ISOTOPE LABELING;

EID: 77955138590     PISSN: 03624803     EISSN: 10991344     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (3)

1. M. Prashad, B. Hu, D. Har, O. Repic, and T. J. Blacklock. Process R&D, Chemical and Analytical Development, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936, U.S.A. Olivier Lohse Process R&D, Chemical and Analytical Development, Novartis Pharma AG, CH-4002 Basel, Switzerland. Org. Process Res. Dev., 2006, 10(1), pp 135-141
2. B. Cuenoud, I. Bruce, R. Fairhurst, D. Beattie. WO 00/75114, December14, 2000.
3. O. Lohse, C. Vogel. (Novartis AG; Novartis Pharma GmbH).Process for preparing 5-[(R)-2-(5,6-diethyl-indian-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H) -quinolin-2-one salt, useful as an adrenoceptor agonist. PCT Int. Appl. (2004), WO 2004076422.